Co-Authors
This is a "connection" page, showing publications co-authored by Kevin Gray and Nathaniel Baker.
Connection Strength
5.220
-
Baker NL, Ramakrishnan V, Gray KM, Carpenter MJ, McClure EA, Tomko RL, Saladin ME. Characterization of salivary progesterone in female smokers. Nicotine Tob Res. 2022 May 09.
Score: 0.238
-
McClure EA, Wahlquist AE, Tomko RL, Baker NL, Carpenter MJ, Bradley ED, Cato PA, Gipson CD, Gray KM. Evaluating N-acetylcysteine for early and end-of-treatment abstinence in adult cigarette smokers. Drug Alcohol Depend. 2021 08 01; 225:108815.
Score: 0.224
-
Sherman BJ, Baker NL, Schmarder KM, McRae-Clark AL, Gray KM. Latency to cannabis dependence mediates the relationship between age at cannabis use initiation and cannabis use outcomes during treatment in men but not women. Drug Alcohol Depend. 2021 01 01; 218:108383.
Score: 0.214
-
McClure EA, Baker NL, Hood CO, Tomko RL, Squeglia LM, Flanagan JC, Carpenter MJ, Gray KM. Cannabis and Alcohol Co-Use in a Smoking Cessation Pharmacotherapy Trial for Adolescents and Emerging Adults. Nicotine Tob Res. 2020 07 16; 22(8):1374-1382.
Score: 0.210
-
Baker NL, Gray KM, Ramakrishnan V, Tomko RL, McClure EA, Carpenter MJ, Saladin ME. Increases in endogenous progesterone attenuate smoking in a cohort of nontreatment seeking women: An exploratory prospective study. Addict Biol. 2021 03; 26(2):e12918.
Score: 0.208
-
Tomko RL, Saladin ME, Baker NL, McClure EA, Carpenter MJ, Ramakrishnan VR, Heckman BW, Wray JM, Foster KT, Tiffany ST, Metts CL, Gray KM. Sex Differences in Subjective and Behavioral Responses to Stressful and Smoking Cues Presented in the Natural Environment of Smokers. Nicotine Tob Res. 2020 01 27; 22(1):81-88.
Score: 0.203
-
Gray KM, Baker NL, McClure EA, Tomko RL, Squeglia LM, Saladin ME, Carpenter MJ. Efficacy and Safety of Varenicline for Adolescent Smoking Cessation: A Randomized Clinical Trial. JAMA Pediatr. 2019 12 01; 173(12):1146-1153.
Score: 0.201
-
Tomko RL, Baker NL, Hood CO, Gilmore AK, McClure EA, Squeglia LM, McRae-Clark AL, Sonne SC, Gray KM. Depressive symptoms and cannabis use in a placebo-controlled trial of N-Acetylcysteine for adult cannabis use disorder. Psychopharmacology (Berl). 2020 Feb; 237(2):479-490.
Score: 0.200
-
Tomko RL, McClure EA, Squeglia LM, Treloar Padovano H, McRae-Clark AL, Baker NL, Carpenter MJ, Gray KM. Methods to reduce the incidence of false negative trial results in substance use treatment research. Curr Opin Psychol. 2019 12; 30:35-41.
Score: 0.190
-
McClure EA, Baker NL, Sonne SC, Ghitza UE, Tomko RL, Montgomery L, Babalonis S, Terry GE, Gray KM. Tobacco use during cannabis cessation: Use patterns and impact on abstinence in a National Drug Abuse Treatment Clinical Trials Network study. Drug Alcohol Depend. 2018 11 01; 192:59-66.
Score: 0.184
-
Baker NL, Gray KM, Sherman BJ, Morella K, Sahlem GL, Wagner AM, McRae-Clark AL. Biological correlates of self-reported new and continued abstinence in cannabis cessation treatment clinical trials. Drug Alcohol Depend. 2018 06 01; 187:270-277.
Score: 0.179
-
Squeglia LM, Tomko RL, Baker NL, McClure EA, Book GA, Gray KM. The effect of N-acetylcysteine on alcohol use during a cannabis cessation trial. Drug Alcohol Depend. 2018 04 01; 185:17-22.
Score: 0.177
-
Tomko RL, Baker NL, McClure EA, Sonne SC, McRae-Clark AL, Sherman BJ, Gray KM. Incremental validity of estimated cannabis grams as a predictor of problems and cannabinoid biomarkers: Evidence from a clinical trial. Drug Alcohol Depend. 2018 01 01; 182:1-7.
Score: 0.174
-
Gray KM, Sonne SC, McClure EA, Ghitza UE, Matthews AG, McRae-Clark AL, Carroll KM, Potter JS, Wiest K, Mooney LJ, Hasson A, Walsh SL, Lofwall MR, Babalonis S, Lindblad RW, Sparenborg S, Wahle A, King JS, Baker NL, Tomko RL, Haynes LF, Vandrey RG, Levin FR. A randomized placebo-controlled trial of N-acetylcysteine for cannabis use disorder in adults. Drug Alcohol Depend. 2017 08 01; 177:249-257.
Score: 0.169
-
Sherman BJ, McRae-Clark AL, Baker NL, Sonne SC, Killeen TK, Cloud K, Gray KM. Gender differences among treatment-seeking adults with cannabis use disorder: Clinical profiles of women and men enrolled in the achieving cannabis cessation-evaluating N-acetylcysteine treatment (ACCENT) study. Am J Addict. 2017 Mar; 26(2):136-144.
Score: 0.165
-
Tomko RL, Saladin ME, McClure EA, Squeglia LM, Carpenter MJ, Tiffany ST, Baker NL, Gray KM. Alcohol consumption as a predictor of reactivity to smoking and stress cues presented in the natural environment of smokers. Psychopharmacology (Berl). 2017 Feb; 234(3):427-435.
Score: 0.163
-
Squeglia LM, Baker NL, McClure EA, Tomko RL, Adisetiyo V, Gray KM. Alcohol use during a trial of N-acetylcysteine for adolescent marijuana cessation. Addict Behav. 2016 12; 63:172-7.
Score: 0.160
-
McClure E, Baker N, Carpenter MJ, Treiber FA, Gray K. Attitudes and interest in technology-based treatment and the remote monitoring of smoking among adolescents and emerging adults. J Smok Cessat. 2017 Jun; 12(2):88-98.
Score: 0.151
-
Saladin ME, McClure EA, Baker NL, Carpenter MJ, Ramakrishnan V, Hartwell KJ, Gray KM. Increasing progesterone levels are associated with smoking abstinence among free-cycling women smokers who receive brief pharmacotherapy. Nicotine Tob Res. 2015 Apr; 17(4):398-406.
Score: 0.145
-
Gray KM, McClure EA, Baker NL, Hartwell KJ, Carpenter MJ, Saladin ME. An exploratory short-term double-blind randomized trial of varenicline versus nicotine patch for smoking cessation in women. Addiction. 2015 Jun; 110(6):1027-34.
Score: 0.145
-
Roten A, Baker NL, Gray KM. Cognitive performance in a placebo-controlled pharmacotherapy trial for youth with marijuana dependence. Addict Behav. 2015 Jun; 45:119-23.
Score: 0.143
-
McClure EA, Baker NL, Gipson CD, Carpenter MJ, Roper AP, Froeliger BE, Kalivas PW, Gray KM. An open-label pilot trial of N-acetylcysteine and varenicline in adult cigarette smokers. Am J Drug Alcohol Abuse. 2015 Jan; 41(1):52-6.
Score: 0.139
-
McClure EA, Baker NL, Gray KM. Cigarette smoking during an N-acetylcysteine-assisted cannabis cessation trial in adolescents. Am J Drug Alcohol Abuse. 2014 Jul; 40(4):285-91.
Score: 0.136
-
McClure EA, Saladin ME, Baker NL, Carpenter MJ, Gray KM. Smoking topography and abstinence in adult female smokers. Addict Behav. 2013 Dec; 38(12):2833-6.
Score: 0.130
-
Lewis AL, Baker N, Carpenter M, Klintworth E, Gray KM. Does physician continuity within a clinical trial increase retention and compliance among adolescent smokers? Adolesc Psychiatry (Hilversum). 2013 Apr 01; 3(2).
Score: 0.127
-
Roten AT, Baker NL, Gray KM. Marijuana craving trajectories in an adolescent marijuana cessation pharmacotherapy trial. Addict Behav. 2013 Mar; 38(3):1788-91.
Score: 0.123
-
Gray KM, Carpenter MJ, Baker NL, DeSantis SM, Kryway E, Hartwell KJ, McRae-Clark AL, Brady KT. A double-blind randomized controlled trial of N-acetylcysteine in cannabis-dependent adolescents. Am J Psychiatry. 2012 Aug; 169(8):805-12.
Score: 0.121
-
Gray KM, Carpenter MJ, Baker NL, Hartwell KJ, Lewis AL, Hiott DW, Deas D, Upadhyaya HP. Bupropion SR and contingency management for adolescent smoking cessation. J Subst Abuse Treat. 2011 Jan; 40(1):77-86.
Score: 0.107
-
Gray KM, Baker NL, Carpenter MJ, Lewis AL, Upadhyaya HP. Attention-deficit/hyperactivity disorder confounds nicotine withdrawal self-report in adolescent smokers. Am J Addict. 2010 Jul-Aug; 19(4):325-31.
Score: 0.105
-
McRae-Clark AL, Gray KM, Baker NL, Sherman BJ, Squeglia L, Sahlem GL, Wagner A, Tomko R. Varenicline as a treatment for cannabis use disorder: A placebo-controlled pilot trial. Drug Alcohol Depend. 2021 12 01; 229(Pt B):109111.
Score: 0.057
-
Hood CO, Tomko RL, Baker NL, Tuck BM, Flanagan JC, Carpenter MJ, Gray KM, Saladin ME, McClure EA. Examining sex, adverse childhood experiences, and oxytocin on neuroendocrine reactivity in smokers. Psychoneuroendocrinology. 2020 10; 120:104752.
Score: 0.052
-
McClure EA, Baker NL, Gray KM, Hood CO, Tomko RL, Carpenter MJ, Ramakrishnan VR, Buchanan CJ, Saladin ME. The influence of gender and oxytocin on stress reactivity, cigarette craving, and smoking in a randomized, placebo-controlled laboratory relapse paradigm. Psychopharmacology (Berl). 2020 Feb; 237(2):543-555.
Score: 0.050
-
Tomko RL, Gray KM, Huestis MA, Squeglia LM, Baker NL, McClure EA. Measuring Within-Individual Cannabis Reduction in Clinical Trials: A Review of the Methodological Challenges. Curr Addict Rep. 2019 Dec; 6(4):429-436.
Score: 0.050
-
Orr RK, Hoehn JL, Col NF. The learning curve for sentinel node biopsy in breast cancer: practical considerations. Arch Surg. 1999 Jul; 134(7):764-7.
Score: 0.049
-
McRae-Clark AL, Baker NL, Gray KM, Killeen T, Hartwell KJ, Simonian SJ. Vilazodone for cannabis dependence: A randomized, controlled pilot trial. Am J Addict. 2016 Jan; 25(1):69-75.
Score: 0.038
-
McRae-Clark AL, Baker NL, Gray KM, Killeen TK, Wagner AM, Brady KT, DeVane CL, Norton J. Buspirone treatment of cannabis dependence: A randomized, placebo-controlled trial. Drug Alcohol Depend. 2015 Nov 01; 156:29-37.
Score: 0.037
-
Saladin ME, Gray KM, McRae-Clark AL, Larowe SD, Yeatts SD, Baker NL, Hartwell KJ, Brady KT. A double blind, placebo-controlled study of the effects of post-retrieval propranolol on reconsolidation of memory for craving and cue reactivity in cocaine dependent humans. Psychopharmacology (Berl). 2013 Apr; 226(4):721-37.
Score: 0.031
-
Carpenter MJ, Baker NL, Gray KM, Upadhyaya HP. Assessment of nicotine dependence among adolescent and young adult smokers: a comparison of measures. Addict Behav. 2010 Nov; 35(11):977-82.
Score: 0.026